Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 3/2016

Open Access 01-03-2016 | Magnetic Resonance

Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging

Authors: Elmar M. Merkle, Christoph J. Zech, Carlo Bartolozzi, Mustafa R. Bashir, Ahmed Ba-Ssalamah, Alexander Huppertz, Jeong Min Lee, Jens Ricke, Michiie Sakamoto, Claude B. Sirlin, Sheng-Long Ye, Mengsu Zeng

Published in: European Radiology | Issue 3/2016

Login to get access

Abstract

Objectives

Liver-specific MRI is a fast-growing field, with technological and protocol advancements providing more robust imaging and allowing a greater depth of information per examination. This article reports the evidence for, and expert thinking on, current challenges in liver-specific MRI, as discussed at the 7th International Forum for Liver MRI, which was held in Shanghai, China, in October 2013.

Methods

Topics discussed included the role of gadoxetic acid-enhanced MRI in the differentiation of focal nodular hyperplasia from hepatocellular adenoma and small hepatocellular carcinoma (HCC) from small intrahepatic cholangiocarcinoma (in patients with chronic liver disease), the differentiation of low-grade dysplastic nodule (DN) from pre-malignant high-grade DN and early HCC, and treatment planning and assessment of treatment response for patients with HCC and colorectal liver metastasis. Optimization of the gadoxetic acid-enhanced MRI protocol to gain robust arterial and hepatobiliary phase images was also discussed.

Results and conclusions

Gadoxetic acid-enhanced MRI demonstrates added value for the detection and characterization of focal liver lesions and shows promise in a number of new indications, including regional liver functional assessment and patient monitoring after therapy; however, more data are needed in some areas, and further developments are needed to translate cutting-edge techniques into clinical practice.

Key Points

• Liver-specific MRI is a fast-growing field, with many technological and protocol advancements.
• Gadoxetic acid-enhanced MRI demonstrates value for detecting and characterizing focal liver lesions.
• Gadoxetic acid-enhanced MRI shows promise in regional functional assessment and patient monitoring.
• Further developments are needed to translate cutting-edge techniques into clinical practice.
Literature
1.
Grieser C, Steffen IG, Seehofer D et al (2013) Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics. Magn Reson Imaging 31:755–760CrossRefPubMed
2.
Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed
3.
Huppertz A, Haraida S, Kraus A et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observations. Radiology 234:468–478CrossRefPubMed
4.
Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Investig Radiol 43:504–511CrossRef
5.
Denecke T, Steffen IG, Agarwal S et al (2012) Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol 22:1769–1775CrossRefPubMed
6.
Mohajer K, Frydrychowicz A, Robbins JB, Loeffler AG, Reed TD, Reeder SB (2012) Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging 36:686–696PubMedCentralCrossRefPubMed
7.
Bieze M, van den Esschert JW, Nio CY et al (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199:26–34CrossRefPubMed
8.
Purysko AS, Remer EM, Coppa CP, Obuchowski NA, Schneider E, Veniero JC (2012) Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 198:115–123CrossRefPubMed
9.
Grazioli L, Olivetti L, Mazza G, Bondioni MP (2013) MR imaging of hepatocellular adenomas and differential diagnosis dilemma. Int J Hepatol 2013:374170PubMedCentralCrossRefPubMed
10.
Yoneda N, Matsui O, Kitao A et al (2012) Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 30:777–782CrossRefPubMed
11.
Pomfret EA, Washburn K, Wald C et al (2010) Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 16:262–278CrossRefPubMed
12.
Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215–1229CrossRefPubMed
13.
Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed
14.
Chong YS, Kim YK, Lee MW et al (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67:766–773CrossRefPubMed
15.
Hwang J, Kim YK, Park MJ et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881–889CrossRefPubMed
16.
Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRefPubMed
17.
Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed
18.
Kim SH, Lee CH, Kim BH et al (2012) Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 36:704–709CrossRefPubMed
19.
Peporte AR, Sommer WH, Nikolaou K, Reiser MF, Zech CJ (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82:e101–e106CrossRefPubMed
20.
Chou CT, Chen YL, Wu HK, Chen RC (2011) Characterization of hyperintense nodules on precontrast T1-weighted MRI: utility of gadoxetic acid-enhanced hepatocyte-phase imaging. J Magn Reson Imaging 33:625–632CrossRefPubMed
21.
Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW (2011) Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 197:W44–W52CrossRefPubMed
22.
Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer (IARC), Lyon
23.
Nakashima O, Sugihara S, Kage M, Kojiro M (1995) Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 22:101–105PubMed
24.
Takayama T, Makuuchi M, Hirohashi S et al (1998) Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28:1241–1246CrossRefPubMed
25.
Akai H, Matsuda I, Kiryu S et al (2012) Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 81:2973–2977CrossRefPubMed
26.
Song KD, Kim SH, Lim HK, Jung SH, Sohn I, Kim HS (2015) Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging. Eur Radiol :1–8
27.
Sirlin CB, Hussain HK, Jonas E et al (2014) Consensus report from the 6th International forum for liver MRI using gadoxetic acid. J Magn Reson Imaging 40:516–529CrossRefPubMed
28.
Kumada T, Toyoda H, Tada T et al (2011) Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 197:58–63CrossRefPubMed
29.
Motosugi U, Ichikawa T, Sano K et al (2011) Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 34:88–94CrossRefPubMed
30.
Takayama Y, Nishie A, Nakayama T et al (2012) Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 81:3072–3078CrossRefPubMed
31.
Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D (2012) Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 265:104–114CrossRefPubMed
32.
Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol :1–10
33.
Bartolozzi C, Battaglia V, Bargellini I et al (2013) Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 38:290–296CrossRefPubMed
34.
Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L (2011) Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (</= 2 cm) HCC in cirrhosis. Eur Radiol 21:1233–1242CrossRefPubMed
35.
Kogita S, Imai Y, Okada M et al (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 20:2405–2413CrossRefPubMed
36.
Sugitani S, Sakamoto M, Ichida T, Genda T, Asakura H, Hirohashi S (1998) Hyperplastic foci reflect the risk of multicentric development of human hepatocellular carcinoma. J Hepatol 28:1045–1053CrossRefPubMed
37.
Inoue T, Kudo M, Komuta M et al (2012) Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 47:1036–1047CrossRefPubMed
38.
Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey J-N, Mahvi D (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1271–1280CrossRefPubMed
39.
Pawlik TM, Choti MA (2007) Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11:1057–1077CrossRefPubMed
40.
Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048CrossRefPubMed
41.
42.
Bae KE, Kim SY, Lee SS et al (2012) Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis 30:617–622CrossRefPubMed
43.
Katsube T, Okada M, Kumano S et al (2012) Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. Eur J Radiol 81:1460–1464CrossRefPubMed
44.
Yamada A, Hara T, Li F et al (2011) Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260:727–733CrossRefPubMed
45.
Chan VO, Das JP, Gerstenmaier JF et al (2012) Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist((R)))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre. Ir J Med Sci 181:499–509CrossRefPubMed
46.
Scharitzer M, Ba-Ssalamah A, Ringl H et al (2013) Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 23:2187–2196CrossRefPubMed
47.
Koh DM, Collins DJ, Wallace T, Chau I, Riddell AM (2012) Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 85:980–989PubMedCentralCrossRefPubMed
48.
Tajima T, Akahane M, Takao H et al (2012) Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases? Jpn J Radiol 30:648–658CrossRefPubMed
49.
Lowenthal D, Zeile M, Lim WY et al (2011) Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 21:832–840CrossRefPubMed
50.
Macera A, Lario C, Petracchini M et al (2013) Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol 23:739–747CrossRefPubMed
51.
(2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
52.
53.
Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRefPubMed
54.
Bashir MR, Gupta RT, Davenport MS et al (2013) Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 37:398–406CrossRefPubMed
55.
Di Martino M, Marin D, Guerrisi A et al (2010) Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816CrossRefPubMed
56.
Haradome H, Grazioli L, Tinti R et al (2011) Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 34:69–78CrossRefPubMed
57.
Kim SH, Kim SH, Lee J et al (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681CrossRefPubMed
58.
Toyota N, Nakamura Y, Hieda M et al (2013) Diagnostic capability of gadoxetate disodium-enhanced liver MRI for diagnosis of hepatocellular carcinoma: comparison with multi-detector CT. Hiroshima J Med Sci 62:55–61PubMed
59.
Kudo M, Matsui O, Sakamoto M et al (2013) Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan. Oncology 84:21–27CrossRefPubMed
60.
Parikh T, Drew SJ, Lee VS et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822CrossRefPubMed
61.
Park MJ, Kim YK, Lee MH, Lee JH (2013) Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol 54:127–136CrossRefPubMed
62.
63.
Schmoll HJ, Van CE, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefPubMed
64.
Seidensticker M, Burak M, Kalinski T et al (2015) Radiation-induced liver damage: correlation of histopathology with hepatobiliary magnetic resonance imaging, a feasibility study. Cardiovasc Intervent Radiol 38:213–221CrossRefPubMed
65.
Seidensticker M, Seidensticker R, Mohnike K et al (2011) Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol 6:40PubMedCentralCrossRefPubMed
66.
Seidensticker M, Seidensticker R, Damm R et al (2014) Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One 9, e112731PubMedCentralCrossRefPubMed
67.
Yuan Y, Andronesi OC, Bortfeld TR et al (2013) Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients. Radiother Oncol 106:378–382CrossRefPubMed
68.
Watanabe H, Kanematsu M, Goshima S et al (2012) Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy? AJR Am J Roentgenol 198:589–595CrossRefPubMed
69.
Ito K, Siegelman ES, Stolpen AH, Mitchell DG (2000) MR imaging of complications after liver transplantation. AJR Am J Roentgenol 175:1145–1149CrossRefPubMed
70.
Mehrzad H, Mangat K (2013) The role of interventional radiology in treating complications following liver transplantation. ISRN Hepatol 89:157–164
71.
Wibmer A, Aliya Q, Steininger R et al (2012) Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Investig Radiol 47:353–358CrossRef
72.
Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A (2013) Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology 269:777–786CrossRefPubMed
73.
Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investig Radiol 40:715–724CrossRef
74.
Erasmus LJ, Hurter D, Naude M, Kritzinger HG, Acho S (2004) A short overview of MRI artefacts. S Afr J Radiol 8:13–17
75.
Pietryga JA, Burke LMB, Marin D, Jaffe TA, Bashir MR (2014) Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology 271:426–434CrossRefPubMed
76.
Zech CJ, Vos B, Nordell A et al (2009) Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Investig Radiol 44:305–310CrossRef
77.
Haradome H, Grazioli L, Tsunoo M et al (2010) Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 32:334–340CrossRefPubMed
78.
Schmid-Tannwald C, Herrmann K, Oto A, Panteleon A, Reiser M, Zech C (2012) Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate. Acta Radiol 53:961–965CrossRefPubMed
79.
Tamada T, Ito K, Yoshida K et al (2011) Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol 80:e284–e288CrossRefPubMed
80.
Tanimoto A, Higuchi N, Ueno A (2012) Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 11:91–97CrossRefPubMed
81.
Bashir MR, Merkle EM (2011) Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol 21:291–294CrossRefPubMed
82.
Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM (2012) Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging 35:611–616CrossRefPubMed
83.
Nagle SK, Busse RF, Brau AC et al (2012) High resolution navigated three-dimensional T(1)-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla. J Magn Reson Imaging 36:890–899PubMedCentralCrossRefPubMed
84.
Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67CrossRefPubMed
85.
Motosugi U, Ichikawa T, Tominaga L et al (2009) Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19:2623–2629CrossRefPubMed
86.
Bashir MR, Breault SR, Braun R, Do RK, Nelson RC, Reeder SB (2014) Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI. Acad Radiol 21:726–732CrossRefPubMed
87.
Jeong HT, Kim MJ, Park MS et al (2012) Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging. J Magn Reson Imaging 35:635–643CrossRefPubMed
88.
Sofue K, Tsurusaki M, Tokue H, Arai Y, Sugimura K (2011) Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 21:2336–2343CrossRefPubMed
89.
Takao H, Akai H, Tajima T et al (2011) MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol 77:325–329CrossRefPubMed
90.
Cruite I, Schroeder M, Merkle EM, Sirlin CB (2010) Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 195:29–41CrossRefPubMed
Metadata
Title
Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging
Authors
Elmar M. Merkle
Christoph J. Zech
Carlo Bartolozzi
Mustafa R. Bashir
Ahmed Ba-Ssalamah
Alexander Huppertz
Jeong Min Lee
Jens Ricke
Michiie Sakamoto
Claude B. Sirlin
Sheng-Long Ye
Mengsu Zeng
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 3/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3873-2

Other articles of this Issue 3/2016

European Radiology 3/2016 Go to the issue

Musculoskeletal

Differentiation of malignant from benign soft tissue tumours: use of additive qualitative and quantitative diffusion-weighted MR imaging to standard MR imaging at 3.0 T

Head and Neck

Clinical significance of three-dimensional measurement of tumour thickness on magnetic resonance imaging in patients with oral tongue squamous cell carcinoma

Urogenital

Magnetization transfer imaging of normal and abnormal testis: preliminary results

Cardiac

Image quality, radiation dose, and diagnostic accuracy of prospectively ECG-triggered high-pitch coronary CT angiography at 70 kVp in a clinical setting: comparison with invasive coronary angiography

Musculoskeletal

Correlation of force control with regional spinal DTI in patients with cervical spondylosis without signs of spinal cord injury on conventional MRI

Contrast Media

Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol